Tag: approval

TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Lysander Funds Limited (“Lysander”), the manager of Canso Credit Income Fund (the “Fund”) (TSX: PBY.UN), announces that, at the special meeting of unitholders of the Fund held on June 4, 2026, unitholders of each class of the Fund have approved a change in the structure of the Fund from a closed-end fund into an exchange-traded fund (the “Conversion”), along with other related changes necessary to facilitate and implement the Conversion.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE IN THIS STOCK EXCHANGE RELEASE BELOW.
Series 1 tranche 1 offering of UAB „Atsinaujinančios energetikos investicijos“ notes under the EUR 25 million Bonds Programme is extended until 11-06-2026:
Closed – End Investment Company Intended for Informed Investors UAB “Atsinaujinančios energetikos investicijos” (hereinafter, the “Company”) is extending its public offering of series 1 tranche 1 EUR 2026/2027 Notes (ISIN LT000013780, hereinafter the “Notes”) until 11 June 2026, moving forward also the issue date of the Notes to 15 June 2026 and their maturity term to 15 July 2027. The Notes are being issued under the EUR 25 million Bond Programme. The base prospectus of the programme (hereinafter, the “Prospectus”) was approved by the Bank of Lithuania on 18 May 2026 and announced by the Company.
According to the final terms of the series 1 tranche 1, approved by the Company (hereinafter, the “Final Terms”, amended terms are attached, together with the Issue Specific Summary and translations thereof into Lithuanian, Latvian and Estonian), the Company is planning to issue up to EUR 5 million of nominal value Notes maturing on 15 July 2027 to investors in Lithuania, Latvia and Estonia.
Summary of the main issue terms:
Series 1 tranche 1 size: up to EUR 5,000,000
Denomination: EUR 1,000
Issue price of the Note: EUR 1,000
Interest rate: 9%
Subscription period: from 20 May 2026 to 11 June 2026 2:30 pm Vilnius time
Settlement and issue date: 15 June 2026
Maturity date: 15 July 2027
Investors wishing to submit a subscription order must contact their brokerage company. The investors, having provided their orders for participation in the offering, should not do anything additionally and their orders are valid, unless they would like to withdraw them, as indicated in the final terms.

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer

Huemul Project is centered on Argentina’s first producing uranium mine; Jaguar reports visible surface mineralization, a potential 4-kilometer copper trend, first-ever sampling of historic mine dumps, and 200 rock samples submitted for assay

Key Takeaways:

Sanofi launches 2026 global employee stock purchase plan

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).